MD, 2015, Copenhagen University, Denmark.
Rebecca joined the Davids Lab in 2017 after completing her residency in hematology at Rigshospitalet – the top-ranked hospital in Denmark.
She is studying how cellular signaling cascades and the microenvironment are affected by BCL-2 and BTK inhibition, and how these results correlate with outcome of clinical trials, with a goal to further tailor CLL treatment at the individual patient level.
Her work is a part of collaboration between DFCI and the Leukemia Lab at Rigshospitalet, Denmark led by Dr. Carsten Niemann. She brings to the Davids Lab prior laboratory experience from working with in vitro sensitivity assays, testing of minimal residual disease in childhood acute lymphoblastic leukemia, as well as her clinical experience in hematology.
In her spare time, she loves drawing, baking, running, and experiencing all the great things that her new city of Boston has to offer.